Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads chest X-Rays to catch lung cancer earlier

NCT ID NCT06044454

Diagnosis Sponsor: NHS Greater Glasgow and Clyde Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing an artificial intelligence software called qXR that automatically analyzes chest X-rays to spot signs of lung cancer. The goal is to see if using AI to prioritize which X-rays need urgent review can speed up the time it takes for patients to get a follow-up CT scan or a final decision. The study involves 60,000 adults in Scotland whose chest X-rays are taken as part of routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
qXR (artificial intelligence software for chest X-ray analysis)
What this could lead to
If successful, this AI could help doctors find lung cancer earlier by flagging suspicious chest X-rays faster, potentially improving survival rates.
What could go wrong
This is a large but early-stage real-world test. The AI may not speed up diagnosis as hoped, or could miss some cancers. It is not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Service deployment within a single health board (NHS Greater Glasgow and Clyde), within the following sectors and hospitals: Clyde Sector * The Royal Alexandra Hospital * Inverclyde Royal Hospital * Vale of Leven Hospital South Sector * Queen Elizabeth University Hospital * New Victoria Hospital * Gartnavel General Hospital * West Glasgow Ambulatory Care Hospital North Sector * Glasgow Royal Infirmary * Stobhill Hospital At each participating site, the investigators will identify all patients referred through the outpatient pathway (including GP-referrals). This will include those with suspected lung cancer referred for CXR.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unconsented patients ≧ 18 years old with frontal chest radiograph, acquired consecutively during usual care through the outpatient (including GP) referral pathway only, whose radiograph has not already been reported (applies to clinical effectiveness and health economic evaluation studies). * Unconsented patients ≧ 18 years old with frontal chest radiograph, sampled from images already acquired and reported in the current or previous calendar year (applies to technical evaluation). * Key stakeholders such as NHS service users, healthcare staff and NHS management (applies to qualitative evaluation). Exclusion Criteria: * Patient has requested that they are removed from the study, or has objected to the use of AI in their routine clinical care and this has been subsequently upheld by the health board (applies to clinical effectiveness study, health economic evaluation and technical evaluation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • Glasgow Royal Infirmary (North Sector)

    Glasgow, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom

  • Queen Elizabeth University Hosp (South Sector)

    Glasgow, United Kingdom

  • The Royal Alexandra Hospital (Clyde Sector)

    Paisley, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.